Aberdeen Group plc Has $19.53 Million Stock Position in Medpace Holdings, Inc. $MEDP

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Aberdeen Group plc lessened its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 1.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 64,109 shares of the company's stock after selling 745 shares during the quarter. Aberdeen Group plc owned about 0.22% of Medpace worth $19,533,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Whittier Trust Co. lifted its stake in Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after buying an additional 35 shares during the period. Benjamin Edwards Inc. raised its position in shares of Medpace by 3.1% during the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock worth $366,000 after purchasing an additional 36 shares during the period. Assetmark Inc. grew its holdings in shares of Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after buying an additional 43 shares in the last quarter. Proficio Capital Partners LLC grew its holdings in shares of Medpace by 6.4% during the first quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock worth $237,000 after buying an additional 47 shares in the last quarter. Finally, Park Avenue Securities LLC grew its holdings in shares of Medpace by 1.8% during the first quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock worth $838,000 after buying an additional 48 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Insider Activity

In other Medpace news, CEO August J. Troendle sold 48,487 shares of Medpace stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the transaction, the chief executive officer directly owned 962,615 shares of the company's stock, valued at approximately $434,803,569.35. The trade was a 4.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kevin M. Brady sold 12,000 shares of Medpace stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the transaction, the chief financial officer directly owned 6,000 shares in the company, valued at $2,725,380. The trade was a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 114,450 shares of company stock worth $51,791,251. 20.30% of the stock is owned by corporate insiders.

Medpace Price Performance

MEDP stock traded up $10.30 during midday trading on Friday, reaching $463.64. 328,935 shares of the stock were exchanged, compared to its average volume of 424,882. The stock has a market capitalization of $13.02 billion, a PE ratio of 34.47, a P/E/G ratio of 2.85 and a beta of 1.42. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $501.30. The company has a fifty day moving average price of $378.86 and a 200 day moving average price of $335.19.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business's quarterly revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of analyst reports. TD Cowen restated a "sell" rating and issued a $366.00 price target (up from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Mizuho lifted their price target on Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Robert W. Baird lifted their price target on Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft lifted their price objective on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. Finally, Barclays lifted their price target on Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, Medpace has an average rating of "Reduce" and an average price target of $406.60.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.